XML 46 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Income and Comprehensive Income (USD $)
In Thousands, except Per Share data, unless otherwise specified
 3 Months Ended 9 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Mar. 31, 2014
Mar. 31, 2013
Molecular diagnostic testing $ 176,191 $ 148,384 $ 565,335 $ 416,304
Companion diagnostic services 6,733 8,088 24,115 22,746
Total revenue 182,924 156,472 589,450 439,050
Costs and expenses:        
Cost of molecular diagnostic testing 23,648 16,462 67,842 45,960
Cost of companion diagnostic services 2,961 3,872 10,379 11,585
Research and development expense 13,397 13,618 47,289 39,125
Selling, general, and administrative expense 87,631 64,602 242,752 180,294
Total costs and expenses 127,637 98,554 368,262 276,964
Operating income 55,287 57,918 221,188 162,086
Other income (expense):        
Interest income 2,498 1,434 5,190 4,187
Other (442) (111) (1,066) (224)
Total other income 2,056 1,323 4,124 3,963
Income before income taxes 57,343 59,241 225,312 166,049
Income tax provision 20,573 21,349 82,719 62,984
Net income 36,770 37,892 142,593 103,065
Earnings per share:        
Basic $ 0.50 $ 0.47 $ 1.87 $ 1.27
Diluted $ 0.48 $ 0.46 $ 1.82 $ 1.23
Weighted average shares outstanding        
Basic 73,821 80,375 76,173 81,219
Diluted 76,374 82,434 78,332 83,544
Net income 36,770 37,892 142,593 103,065
Comprehensive income:        
Unrealized gain on available-for-sale securities, net of tax 45 259 583 268
Change in foreign currency translation adjustment, net of tax (672) (497) (280) (566)
Comprehensive income $ 36,143 $ 37,654 $ 142,896 $ 102,767